Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.
The company said the finding requires confirmation in prospective clinical trials.
Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.
Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.
The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.
The finding is based on an analysis that combines results from a Phase 3 trial and a “real-world” retrospective cohort of patients with severe disease, the company said, noting that it requires confirmation in prospective clinical trials.
The company will present the data at the Virtual COVID19 Conference as part of the 23rd International AIDS Conference, according to a statement. The treatment has been given emergency use authorization for hospitalized patients with severe symptoms by the U.S. Food and Drug Administration.
Gilead shares were up nearly 2% at $76.14 in trading before the bell.
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.